If You Invested in Sensus Healthcare Inc (SRTS)

Sensus Healthcare, Inc. (Nasdaq: SRTS) is a medical device company in the surgical and medical instrument manufacturing industry that focuses on non-invasive and minimally-invasive treatments for oncological and non-oncological skin conditions. According to the company’s public disclosures, Sensus Healthcare is described as a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Its technology platform is based on superficial radiotherapy (SRT and image-guided SRT, or IG-SRT), which is used by healthcare providers as a patient-centric treatment option.

The company develops and manufactures superficial radiotherapy systems that are used to treat basal cell and squamous cell skin cancers and other skin conditions such as keloids, as described in prior company information. Sensus Healthcare’s product portfolio has included the SRT-100, SRT-100 Vision, and a Sentinel software and service program, and the company has reported that a significant portion of its revenue is generated from customers in the United States. In its more recent communications, Sensus emphasizes its SRT and IG-SRT technology as a platform designed to be safe, precise and adaptable to a variety of clinical settings.

Sensus Healthcare positions its systems as non-surgical alternatives for the treatment of non-melanoma skin cancer and keloids. Company news releases highlight the use of SRT and IG-SRT as non-invasive options that can be delivered in dermatology, radiation oncology and skin cancer treatment settings. The company also notes that its approach is intended to be cost-effective for practices and patients, reflecting a focus on both clinical outcomes and economics.

Technology and clinical focus

Across multiple press releases, Sensus Healthcare describes its core technology as superficial radiotherapy (SRT and IG-SRT). This modality delivers radiation at the skin surface for the treatment of non-melanoma skin cancer (NMSC) and keloids. The company cites published clinical work, including a study in Dermatologic Therapy, that evaluated Sensus’ SRT technology combined with punch excision for treating keloids. That study reported statistically significant improvements in pain, itching, thickness and irregularity of keloid scars after one year of follow-up, with no severe adverse reactions reported, reinforcing the safety profile of SRT as presented by the company.

Sensus Healthcare’s communications also reference the use of SRT beyond aesthetics, emphasizing its medical relevance for serious skin conditions. The company highlights that keloids can cause significant physical and emotional burden and presents SRT as part of combination therapy strategies, such as following punch excision debulking, to address multiple and extensive keloids.

Reimbursement and commercial model

Recent company updates describe an important reimbursement development for Sensus Healthcare’s technology. The Centers for Medicare & Medicaid Services (CMS) has published a distinct set of Current Procedural Terminology (CPT) treatment codes specific to the use of superficial radiotherapy (SRT and IG-SRT) for non-melanoma skin cancer. Sensus states that these SRT-dedicated CPT codes reflect CMS’ acknowledgement of SRT as a standalone treatment modality for NMSC and provide strengthened reimbursement certainty for physicians delivering SRT therapies.

In its financial reporting and commentary, Sensus Healthcare notes that the new coding represents a reimbursement milestone and that it has been working toward this outcome since the company was founded. The company also reports that this coding update supports its strategy to broaden its commercial footprint in dermatology, radiation oncology and skin cancer treatment settings. In addition, Sensus references a Fair Deal Agreement (FDA) program, under which treatment volume growth has been discussed in its financial results, and indicates that this program is part of its commercial approach to placing systems and supporting recurring treatment volumes.

Operations, markets and growth indicators

Sensus Healthcare describes itself as having an expanding international footprint and references shipments of SRT systems to international markets, including China, as well as groundwork for broader expansion following MDSAP certification. At the same time, the company reports that a substantial portion of its revenue is generated from customers in the United States. Its communications emphasize adoption of SRT and IG-SRT among dermatology and oncology practices and the use of its systems across U.S. and international markets.

In a recognition reported by the company, Sensus Healthcare was named to TIME’s list of America’s Growth Leaders of 2026, a ranking of 500 U.S. publicly traded companies developed with Statista. The company states that this ranking reflects revenue growth, financial stability and stock performance over a multi-year period, and that its position in the top 100 highlights commercial momentum, global expansion and growing adoption of its SRT and IG-SRT systems for non-invasive treatment of non-melanoma skin cancer and keloids.

Corporate governance and stock information

Sensus Healthcare, Inc. is listed on The Nasdaq Stock Market under the ticker symbol SRTS. The company files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), including Forms 10-K, 10-Q and 8-K. Recent Form 8-K filings describe board-level changes, such as the appointment of independent directors to the Board of Directors. These filings note that the Board has determined certain directors to be independent under Nasdaq listing standards and outline committee assignments, such as membership on the Audit Committee.

The company’s SEC filings and news releases also reference the use of non-GAAP financial measures, including Adjusted EBITDA, which management uses in analyzing performance. Reconciliations between GAAP and non-GAAP measures are provided in the company’s earnings press releases, which are furnished as exhibits to its Form 8-K filings.

Risk factors and external environment

In its financial communications, Sensus Healthcare notes that geopolitical events such as the Middle East conflict and the Russian invasion of Ukraine had not, at the time of disclosure, had any significant impact on its business, while indicating that it continues to monitor developments and would address them in future disclosures if applicable. The company also notes that its forward-looking statements are subject to risks and uncertainties, as is standard in its press releases and SEC filings.

Business highlights and positioning

Across its public communications, Sensus Healthcare emphasizes several themes:

• A focus on non-invasive and minimally-invasive treatments for oncological and non-oncological skin conditions.
• Use of superficial radiotherapy (SRT and IG-SRT) as a dedicated modality for non-melanoma skin cancer and keloids.
• Presentation of its technology as patient-centric, with attention to clinical outcomes and patient experience.
• Efforts to secure and implement dedicated reimbursement codes that recognize SRT as a standalone treatment option.
• Expansion of its commercial presence in the United States and selected international markets.

Investors researching Sensus Healthcare (SRTS) can review the company’s SEC filings for detailed financial and risk information, and its press releases for updates on technology, reimbursement, clinical data, and corporate governance developments.